| Literature DB >> 35811362 |
Hae-Rim Kim1, Seong-Hyop Kim2,3.
Abstract
Our understanding and management of rheumatoid arthritis (RA) have greatly improved, but perioperative and anesthetic management remain challenging. RA is not limited to joints; systemic evaluation is thus required when planning perioperative management. Especially, careful airway evaluation is needed; management of airway-related arthritis is challenging. A multidisciplinary approach is essential to prevent complications without exacerbating RA disease activity. Guidelines published in 2017 are available for perioperative management of anti-rheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. However, the guidelines focus only on anti- rheumatic medications, and do not consider all aspects of perioperative management (including anesthesia). Here, we discuss the perioperative and anesthetic management of patients with RA.Entities:
Keywords: Anesthesia; Arthritis, rheumatoid; Operation; Surgery
Mesh:
Substances:
Year: 2022 PMID: 35811362 PMCID: PMC9271718 DOI: 10.3904/kjim.2021.555
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 3.165
Extraarticular and systemic aspects of rheumatoid arthritis that must be considered during perioperative and anesthetic management
| Organ | Extraarticular involvement |
|---|---|
| Neurological system | Central neuropathy |
| Ocular system | Kerato-conjuctivitis |
| Cardiovascular system | Pericarditis, pericardial effusion, cardiac tamponade |
| Respiratory system | Reduced chest wall compliance (costochondral disease) |
| Hematological system | Anemia [chronic disease, iron deficiency (bleeding) and bone marrow suppression from medication] |
| Hepatic system | Hepatic fibrosis |
| Renal system | Glomerulonephritis |
| Skin | Fragile skin |
| Musculoskeletal system | Osteoporosis |
Common adverse effects associated with medications for rheumatoid arthritis and recommendations on how to deal with them during elective surgical procedures
| Medication | Adverse effect | Administration during surgical procedures | |
|---|---|---|---|
| Corticosteroid | Hypertension, infection, electrolyte imbalance, weight gain, glucose intolerance, adrenal insufficiency, fragile skin | See | |
|
| |||
| Conventional DMARDs | Methotrexate | Pulmonary toxicity, bone marrow suppression, hepatotoxicity, infection | Continue |
| Hydroxychloroquine | Retinal toxicity, cardiotoxicity, blood dyscrasia | Continue | |
| Sulfasalazine | Central nervous system symptoms, granulocytopenia, hemolytic anemia | Continue | |
| Leflunomide | Hepatotoxicity, myelosuppression infection, pulmonary toxicity | Continue | |
|
| |||
| Biologic DMARDs | Etanercept, infliximab, adalimumab, golimumab | Infection, drug-induced lupus, neurologic deficit, heart failure, hepatitis B reactivation | Withhold before surgery and schedule surgery at the end of the dosing cycle |
|
| |||
| B cell inhibitor | Rituximab | Infection, infusion reaction, cytopenia, hepatitis B reactivation | Withhold before surgery and schedule surgery at the end of the dosing cycle |
|
| |||
| IL-6 inhibitor | Tocilizumab | Infection, cytopenia,, increased liver enzyme, dyslipidemia | Withhold before surgery and schedule surgery at the end of the dosing cycle |
|
| |||
| T cell costimulatory inhibitor | Abatacept | Infection | Withhold before surgery and schedule surgery at the end of the dosing cycle |
|
| |||
| Targeted synthetic DMARD | JAK inhibitor (tofacitinib, baricitinib, upadacitinib) | Infection, neutropenia, increased liver enzyme, dyslipidemia | Withhold at least 7 days prior surgery |
DMARD, disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor; SQ, subcutaneous; IV, intravenous; IL, interleukin; JAK, Janus kinase.
Recommended steroid doses during surgery
| Surgery type | Endogenous cortisol secretion rate | Examples | Recommended steroid dosing |
|---|---|---|---|
| Superficial | 8–10 mg/day (baseline) | Dental surgery | Usual daily dose |
| Minor | 50 mg/day | Inguinal hernia | Usual daily dose |
| Moderate | 75–150 mg/day | Low extremity revascularization | Usual daily dose |
| Major | 75–150 mg/day | Esophagectomy | Usual daily dose |
IV, intravenous.
Figure 1Perioperative management of rheumatoid arthritis patients.